Plain-English translation of NCT05420948 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an immunotherapy medication, works better when combined with occasional chemotherapy for advanced head and neck cancer. Doctors will use a special blood test that measures tumor DNA to decide when to add chemotherapy. All the drugs in this study are already approved by the FDA, but this is a new way of using them together based on what the blood test shows.
Right now, doctors aren't sure whether giving chemotherapy on and off — guided by blood test results — might work better than immunotherapy alone. This trial hopes to find out if watching tumor DNA in the blood can help them use the treatment more effectively and reduce unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
You will receive the immunotherapy medication through an IV needle in your arm every 3 weeks for at least 2 cycles (about 6 weeks). Depending on which group you're assigned to, you may also receive chemotherapy on the same days. Throughout the study, you'll have blood tests to measure tumor DNA, which will help doctors decide if and when to add chemotherapy. Your participation will last about 2 years, with regular clinic visits for treatment, blood work, and scans to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States